Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the month of August 2026, with the report dated August 11, 2026. The company is a foreign private issuer based in Lausanne, Switzerland, focused on developing therapies for neurodegenerative diseases.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes and Developments
- Regulatory Milestone: AC Immune SA received Fast Track designation and clearance of its Investigational New Drug (IND) application from the U.S. FDA for its candidate ACI-7104.
- Candidate Details: ACI-7104 is a wholly owned anti-alpha-synuclein (a-syn) active immunotherapy designed to treat early-stage Parkinson's disease (PD).
- Mechanism: The therapy induces a-syn-specific antibodies that preferentially recognize aggregated a-syn species toxic to neurons.
- Clinical Status: The candidate is currently being investigated in the VacSYn Phase 2 trial, an adaptive, biomarker-based study.
Outlook and Management Commentary
Management indicates that final Part 1 week-100 results for the VacSYn Phase 2 trial are on track to be announced in the second half (H2) of the current year. The filing incorporates the press release dated August 11, 2026, by reference into the company's registration statements.
Investor Verification Checklist
- Verify the specific scope of the FDA Fast Track designation for ACI-7104.
- Confirm the exact timeline for the announcement of the VacSYn Phase 2 trial Part 1 week-100 results.
- Review the company's cash runway and funding status, as no financial data was included in this specific filing.
- Monitor for any updates regarding the adaptive design of the VacSYn trial.